Objective To study the clinical significance of HBsAg and HBeAg quantitative detection in antiviral treatment. Methods Total of 152 patients with chronic hepatitis B selected from the author’s hospital received antiviral treatment with interferon and nucleoside analogues. After 12 weeks, 24 weeks and 52 weeks of treatment, quantitative detections of HBsAg, HBeAg and HBV DNA have been carried out so as to observe the correlation between the quantitative detection and the treatment effect. Results For the interferon treatment group:the changes of HBeAg after 12 weeks and HBeAg after 24 weeks have correlation with long-term outcome, which is of statistical signiifcance (both P<0.05);for the nucleoside analogues treatment group:HBsAg quantitative didn’t change signiifcantly in the course of treatment, and the changes of HBeAg after 12 weeks and 24 weeks have been found to be associated with the prognosis of the patients, which also has statistical signiifcance (both P<0.05);HBeAg can serve as a reference index for forecasting the risk of drug resistance. Conclusions HBsAg and HBeAg are two stable and reliable biological markers;the quantitative detection can visually analyze the patients’ conditional changes, predict therapeutic response and help formulate the individualized treatment plan.%目的：探讨HBsAg、HBeAg定量检测在CHB抗病毒治疗中的临床意义。方法选择本院门诊及住院CHB患者152例，应用干扰素、核苷（酸）类似物抗病毒治疗，在治疗前、12周、24周、52周定量检测HBsAg、HBeAg、HBV DNA定量，观察HBsAg、HBeAg与治疗疗效的相关性。结果干扰素治疗组12周HBeAg的变化及24周HBsAg变化与治疗远期效果有相关性，差异均有统计学意义（P均＜0.05）；核苷类似物治疗组HBsAg定量在治疗过程中变化不明显，12周、24周HBeAg变化与患者预后有关，差异均有统计学意义（P均＜0.05），HBeAg可做为预测耐药风险的参考指标。结论HBsAg、HBeAg是两个稳定、可靠的生物学标志，两者定量检测可以直观地分析患者病情变化，预测治疗应答情况，帮助制定个体化治疗方案。
展开▼
